search
Back to results

CICERO- A Care Home Study of COVID-19

Primary Purpose

COVID

Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Q16 testing
Nasopharyngeal swab and main laboratory
Sponsored by
Queen Mary University of London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for COVID focused on measuring COVID-19

Eligibility Criteria

18 Years - 130 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Persons resident or requiring access to the care home
  • Capable of giving written informed consent, or if appropriate, having an acceptable individual capable of giving consent on the participant's behalf.

Exclusion Criteria:

  • Persons not providing informed consent or withdrawing consent at any time during the study.
  • Persons requiring urgent and immediate access to the care home, for example medical staff attending emergency visits.
  • Persons unable to provide nasal or oropharyngeal swabs for medical reasons.

Sites / Locations

  • Queen Mary University London

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard of care

Near Patient Testing

Arm Description

Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14

Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14, with the addition of daily nasal swabs tested via rapid test system

Outcomes

Primary Outcome Measures

CoV-2 Infection after 21 days
The cumulative number of confirmed cases of CoV-2 infection after 21 days, measured by PCR detection of CoV-2, within the care home residents, staff and visitors

Secondary Outcome Measures

CoV-2 Infection after 14 days
The cumulative number of confirmed cases of CoV-2 infection after 14 days, measured by PCR detection of CoV-2, within the care home residents, staff and visitors.
Cases of suspected or confirmed CoV-2 infection
The cumulative number of suspected or confirmed cases of CoV-2 infection after 14 days, within the care home residents, staff and visitors.
Hospitalisation and death
The cumulative number of confirmed COVID-19-related hospitalisations and deaths of care home residents, staff and visitors after 21 and 40 days.

Full Information

First Posted
June 29, 2020
Last Updated
July 31, 2023
Sponsor
Queen Mary University of London
search

1. Study Identification

Unique Protocol Identification Number
NCT04453553
Brief Title
CICERO- A Care Home Study of COVID-19
Official Title
COVID-19 in Vitro Diagnostic Near-patient Testing in Care Environments Using a Cluster Randomised Open-label Trial Design in an East London Care Home Population
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Terminated
Why Stopped
Change in government policy on testing
Study Start Date
July 2, 2020 (Actual)
Primary Completion Date
October 27, 2020 (Actual)
Study Completion Date
October 27, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Queen Mary University of London

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of the study is to determine whether, at 21 days, care homes that implemented near-patient daily testing have a lower rate of confirmed CoV-2 infections than care homes following the DHSC standard of care testing of symptomatic residents.
Detailed Description
Accurate, rapid, near-patient testing systems, such as q16+CoV-2, allow for daily routine testing of residents, and of staff and visitors prior to entering the care home. Daily CoV-2 PCR testing with high analytical sensitivity (e.g., 2 copies per 8 µl sample) may detect infected residents and visitors before clinical symptoms are apparent. Earlier detection may lead to earlier implementation of the UK standard of care protocol for Infection prevention and control measures, thereby preventing the asymptomatic infected individuals from introducing and/or transmitting CoV-2 within the care home. This should reduce the transmission by: Preventing the introduction of the virus into care homes from external visitors e.g., GPs (Inward transmission) Preventing the spread of the virus within care homes and preventing cluster development (internal transmission) Preventing the outward spread of the virus from within care homes by infection of external visitors (Outward transmission)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID
Keywords
COVID-19

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
randomised cluster trial of care homes
Masking
None (Open Label)
Masking Description
No masking will be used as the study arms have different testing patterns
Allocation
Randomized
Enrollment
461 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard of care
Arm Type
Active Comparator
Arm Description
Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14
Arm Title
Near Patient Testing
Arm Type
Experimental
Arm Description
Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14, with the addition of daily nasal swabs tested via rapid test system
Intervention Type
Diagnostic Test
Intervention Name(s)
Q16 testing
Intervention Description
Nasal swab tested on a rapid near patient device
Intervention Type
Diagnostic Test
Intervention Name(s)
Nasopharyngeal swab and main laboratory
Intervention Description
Standard of care testing
Primary Outcome Measure Information:
Title
CoV-2 Infection after 21 days
Description
The cumulative number of confirmed cases of CoV-2 infection after 21 days, measured by PCR detection of CoV-2, within the care home residents, staff and visitors
Time Frame
21 days
Secondary Outcome Measure Information:
Title
CoV-2 Infection after 14 days
Description
The cumulative number of confirmed cases of CoV-2 infection after 14 days, measured by PCR detection of CoV-2, within the care home residents, staff and visitors.
Time Frame
14 days
Title
Cases of suspected or confirmed CoV-2 infection
Description
The cumulative number of suspected or confirmed cases of CoV-2 infection after 14 days, within the care home residents, staff and visitors.
Time Frame
14 days
Title
Hospitalisation and death
Description
The cumulative number of confirmed COVID-19-related hospitalisations and deaths of care home residents, staff and visitors after 21 and 40 days.
Time Frame
21 days and 40 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
130 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Persons resident or requiring access to the care home Capable of giving written informed consent, or if appropriate, having an acceptable individual capable of giving consent on the participant's behalf. Exclusion Criteria: Persons not providing informed consent or withdrawing consent at any time during the study. Persons requiring urgent and immediate access to the care home, for example medical staff attending emergency visits. Persons unable to provide nasal or oropharyngeal swabs for medical reasons.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joanne Martin
Organizational Affiliation
Queen Mary University London
Official's Role
Study Chair
Facility Information:
Facility Name
Queen Mary University London
City
London
ZIP/Postal Code
E1 2ES
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
Citation
Public Health England. Outbreaks in Care Homes in England. Cumulative data to 17th May 2020
Results Reference
background
Citation
University of Cambridge, MRC Biostatistics Unit. Nowcasting and Forecasting of COVID-19
Results Reference
background
Citation
Comas-Herrera A and Zalakain J. Mortality associated with COVID-19 outbreaks in care homes: early international evidence. 12th April 2020
Results Reference
background
PubMed Identifier
32220208
Citation
McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, Lewis J, Baer A, Kawakami V, Lukoff MD, Ferro J, Brostrom-Smith C, Rea TD, Sayre MR, Riedo FX, Russell D, Hiatt B, Montgomery P, Rao AK, Chow EJ, Tobolowsky F, Hughes MJ, Bardossy AC, Oakley LP, Jacobs JR, Stone ND, Reddy SC, Jernigan JA, Honein MA, Clark TA, Duchin JS; Public Health-Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N Engl J Med. 2020 May 21;382(21):2005-2011. doi: 10.1056/NEJMoa2005412. Epub 2020 Mar 27.
Results Reference
background
PubMed Identifier
32240128
Citation
Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Chisty Z, Bell JM, Methner M, Harney J, Jacobs JR, Carlson CM, McLaughlin HP, Stone N, Clark S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Russell D, Hiatt B, Gant J, Duchin JS, Clark TA, Honein MA, Reddy SC, Jernigan JA; Public Health - Seattle & King County; CDC COVID-19 Investigation Team. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):377-381. doi: 10.15585/mmwr.mm6913e1.
Results Reference
background
PubMed Identifier
32271726
Citation
Roxby AC, Greninger AL, Hatfield KM, Lynch JB, Dellit TH, James A, Taylor J, Page LC, Kimball A, Arons M, Schieve LA, Munanga A, Stone N, Jernigan JA, Reddy SC, Lewis J, Cohen SA, Jerome KR, Duchin JS, Neme S. Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults - Seattle, Washington, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):416-418. doi: 10.15585/mmwr.mm6914e2.
Results Reference
background
Citation
World Health Organisation (WHO). Coronavirus disease 2019 (COVID-19) situation report 73. 2020
Results Reference
background
PubMed Identifier
32183930
Citation
Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020 Mar;25(10):2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180. Erratum In: Euro Surveill. 2020 Jun;25(22):
Results Reference
background
PubMed Identifier
32203294
Citation
Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. Nat Biotechnol. 2020 May;38(5):515-518. doi: 10.1038/d41587-020-00010-2. No abstract available.
Results Reference
background
Citation
Department of Health & Social Care. COVID-19: Our Action Plan for Adult Social Care. 15th April 2020
Results Reference
background
PubMed Identifier
32296168
Citation
He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo X, Chen Y, Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling BJ, Li F, Leung GM. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020 May;26(5):672-675. doi: 10.1038/s41591-020-0869-5. Epub 2020 Apr 15. Erratum In: Nat Med. 2020 Sep;26(9):1491-1493.
Results Reference
background
Citation
Foundation for Innovative New Diagnostics. SARS-CoV-2 Molecular Assay Evaluation: Results
Results Reference
background
Citation
Primerdesign™ Ltd. Primerdesign Ltd COVID-19 genesig® Real-Time PCR assay. Instructions for Use. Issue 1.01. 20th March 2020. Available at: https://www.fda.gov/media/136309/download (page 21)
Results Reference
background
PubMed Identifier
26518469
Citation
Ip DKM, Lau LLH, Chan KH, Fang VJ, Leung GM, Peiris MJS, Cowling BJ. The Dynamic Relationship Between Clinical Symptomatology and Viral Shedding in Naturally Acquired Seasonal and Pandemic Influenza Virus Infections. Clin Infect Dis. 2016 Feb 15;62(4):431-437. doi: 10.1093/cid/civ909. Epub 2015 Oct 30.
Results Reference
background
Citation
NHS, PHE, DHSC and CQC. Admission and Care of Patients during COVID-19 Incident in a Care Home. 2nd April 2020. Version 1.
Results Reference
background

Learn more about this trial

CICERO- A Care Home Study of COVID-19

We'll reach out to this number within 24 hrs